Senti Biosciences Holdings, Inc.

Listed Company

SNTICIK 0001854270NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$22.0K

Net Income

$-61.44M

Total Assets

—

Equity

—

Shares Out

31.14M

Op. Cash Flow

$-43.44M

SNTI$0.44−78.41% · past yearDBEQ Basic

Daily closing prices

Business

Senti Biosciences is a clinical-stage biotechnology company developing next-generation cell and gene therapies using proprietary gene circuit platform technologies for patients with incurable diseases. The company's lead product candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy currently in Phase 1 clinical trials for relapsed/refractory hematological malignancies including acute myeloid leukemia. Senti's gene circuit platform comprises logic gating, multi-arming, regulator dials, and smart sensors designed to enhance precision and control of cell and gene therapies. The company operates primarily in oncology with additional programs in regenerative medicine through partnerships with BlueRock Therapeutics, manufacturing services outsourced to GeneFab.

Summary from 10-K filed 2026-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue - related party	22,000	0	2	3	2
Research and development (including related party costs of $12,909 and $14,266 for the year ended December 31, 2025 and 2024, respectively)	38	34	32	28	22
General and administrative	26	26	37	38	21
Impairment of long-lived assets	5	300,000	26	0	−22,000
Total operating expenses	69	61	95	66	43
Loss from operations	−69	−61	−93	−62	−40
Interest income	927,000	948,000	3	2	11,000
Other income, net	800,000	200,000	−33,000	−32,000	−120,000
Change in fair value of Preferred Stock Tranche Liability - related party	0	13	0	—	—
Change in fair value of contingent earnout liability	0	20,000	200,000	10	0
Total other income, net	7	8	9	12	−15
Net loss	−61	−53	−71	−58	−55
Comprehensive loss	−61	−53	−71	−58	−55
Net loss per share, basic (in dollars per share)	−2.73	−12.03	−16.01	−2.23	−19
Net loss per share, diluted (in dollars per share)	−2.73	−12.03	−16.01	−2.23	−19
Weighted-average shares outstanding, basic (in shares)	22	5	4	26	3
Weighted-average shares outstanding, diluted (in shares)	22	5	4	26	3

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	16	48	36	58	56
Total current assets	23	59	71	103	60
Restricted cash	4	4	4	3	3
Property and equipment, net	13	21	25	51	12
Operating lease right-of-use assets	12	14	16	18	21
Other non-current assets	19,000	105,000	215,000	283,000	176,000
TOTAL ASSETS	51	98	119	181	97
Accounts payable	3	1	1	1	5
Accrued expenses and other current liabilities	5	6	6	13	5
Operating lease liabilities, current	5	5	4	2	2
Deferred revenue, current - related party	43,000	0	0	799,000	2
GeneFab sublease deferred income - related party	304,000	660,000	989,000	0	—
Total current liabilities	14	13	13	18	15
Operating lease liabilities, non-current	24	29	34	35	21
Other non-current liabilities	8	5	0	—	—
TOTAL LIABILITIES	46	47	53	54	36
Commitments and contingencies (Note 13)	—	—	—	—	—
Series A redeemable convertible preferred stock, $0.0001 par value; zero and 21,200 shares authorized as of December 31, 2025 and 2024, respectively; zero and 21,157 shares issued and outstanding as of December 31, 2025 and 2024, respectively; aggregate liquidation preference of zero and $147,647 as of December 31, 2025 and 2024, respectively	0	25	0	0	172
Common stock, $0.0001 par value; 500,000,000 shares authorized as of both December 31, 2025 and 2024; 30,879,355 and 4,829,035 shares issued and outstanding as of December 31, 2025 and 2024, respectively	3,000	1,000	1,000	4,000	0
Additional paid-in capital	364	323	311	301	4
Accumulated deficit	−359	−297	−244	−173	−115
TOTAL STOCKHOLDERS EQUITY	6	26	67	127	−111
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	51	98	119	181	97

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	6	2	10	16	2
Depreciation	4	4	4	1	800,000
Change in fair value of Preferred Stock Tranche liability - related party	0	−13	0	—	—
Other non-cash charges	39,000	115,000	35,000	8,000	0
Operating lease right-of-use assets	2	2	—	—	—
Accounts payable	2	797,000	−290,000	186,000	−617,000
Accrued expenses and other current liabilities	559,000	−671,000	716,000	2	3
Operating lease liabilities	−5	−4	484,000	14	−1
GeneFab sublease deferred income - related party	−356,000	−329,000	689,000	0	—
Deferred revenue, current - related party	43,000	0	—	—	—
Other non-current liabilities	0	149,000	0	—	—
Net cash used in operating activities	−43	−41	−52	−35	−35
Purchases of property and equipment	−196,000	−26,000	−12	−41	−6
Proceeds from sale of property and equipment	12,000	60,000	105,000	0	—
Net cash provided by (used in) investing activities	−184,000	34,000	30	−82	−6
Proceeds from CIRM Grant	3	5	0	521,000	2
Payment of issuance costs	−2	−229,000	0	—	—
Proceeds from private placement, net of fees paid to investor	0	47	0	—	—
Net cash provided by financing activities	12	54	779,000	119	68
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	−32	12	−22	2	28
Unpaid Issuance Costs	34,000	2	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Senti Biosciences Holdings, Inc.'s CIK number?

Senti Biosciences Holdings, Inc.'s SEC CIK number is 0001854270 (1854270). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Senti Biosciences Holdings, Inc.'s SEC filings?

All of Senti Biosciences Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Senti Biosciences Holdings, Inc. last report earnings?

Senti Biosciences Holdings, Inc. (SNTI) most recently filed an earnings 8-K with the SEC on Jul 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-048248). This is Senti Biosciences Holdings, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Senti Biosciences Holdings, Inc.'s most recent earnings 8-K?

Senti Biosciences Holdings, Inc.'s latest earnings 8-K (Item 2.02) was filed Jul 15, 2026 under accession 0001628280-26-048248. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Senti Biosciences Holdings, Inc.'s latest earnings 8-K →
Look up any company's CIK number →